Trials / Withdrawn
WithdrawnNCT04184518
Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma
Phase II, Open-Label Study of Preliminary Efficacy of Durvalumab (MEDI4736) in Combination With Cediranib in Patients With Metastatic Uveal Melanoma
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Grupo Español Multidisciplinar de Melanoma · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase II clinical trial aimed to evaluate the efficacy of the combination of cediranib and durvalumab in patients with metastatic uveal melanoma (mUM) with biopsiable disease at first line of after failure to first line systemic or liver directed therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cediranib Maleate | Cediranib 20mg, oral, 5 days on and 2 days off until disease progression |
| DRUG | Durvalumab | Durvalumab 1500mg, intravenous, every 4 weeks until disease progression |
Timeline
- Start date
- 2020-05-01
- Primary completion
- 2021-12-01
- Completion
- 2021-12-01
- First posted
- 2019-12-03
- Last updated
- 2020-06-02
Locations
5 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT04184518. Inclusion in this directory is not an endorsement.